Celltrion Solidifies "No. 1 Market Share" Position in Key Asian Countries

Remsima Achieves 93% Market Share in Singapore, 84% in Hong Kong
Celltrion Accelerates Launch of Omliclo, Stoboclo-Ossenbelt, and Stekimma

Celltrion is strengthening its market influence by expanding prescription performance for its major product lines, including autoimmune disease and oncology, across Asia.

On August 19, Celltrion announced that it operates a direct sales system led by local subsidiaries in key Asian markets such as Malaysia, Singapore, and Thailand. As a result, many of its major product lines continue to maintain the number one market share in several countries.

According to pharmaceutical market research firm IQVIA, as of the first quarter of this year, Celltrion's autoimmune disease treatment "Remsima" (ingredient: infliximab) retained the top market share in Singapore (93%), Hong Kong (84%), Thailand (78%), and Malaysia (72%).

During the same period, the blood cancer treatment "Truxima" (ingredient: rituximab) also held the number one position in Singapore (93%) and Thailand (78%), while the breast and gastric cancer treatment "Herzuma" (ingredient: trastuzumab) maintained a leading prescription share in Malaysia (51%) and Thailand (42%).

In Asia's mostly bidding-based markets, Celltrion has expanded its contracts by emphasizing supply stability and providing timely deliveries, thereby earning the trust of local medical institutions. In addition, by actively participating in major local conferences to promote the clinical value and competitiveness of its products, and by strengthening its network with key opinion leader (KOL) groups, Celltrion has been increasing product awareness and prescription preference.

The performance of existing product lines is expected to lead to follow-up high-profit products. In the second half of this year, Celltrion plans to launch the allergy treatment "Omriclo" (ingredient: omalizumab) and bone disease treatment "Stovoclo-Osenvelt" (ingredient: denosumab) in Thailand. In addition, in Malaysia and Singapore, the company plans to strengthen its product portfolio by releasing the autoimmune disease treatment "Stekima" (ingredient: ustekinumab) within the year.

A Celltrion official stated, "We plan to strengthen sales activities to ensure the strong performance of our current product lines leads to success for new products," and added, "Through these efforts, we will focus our business capabilities to further accelerate performance growth in the Asian region."

This content was produced with the assistance of AI translation services.